Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is April 23, 2025, covering a share repurchase executed on April 22, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial performance metrics such as revenue or profit.
- Shares Purchased: 711,400 ordinary shares.
- Price Range: Lowest price paid was 1,329.50 GBp; highest price paid was 1,363.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,344.86 GBp.
- Treasury Shares Held: 200,367,225 ordinary shares (post-transaction).
- Shares in Issue: 4,114,871,233 ordinary shares (excluding Treasury shares).
- Total Voting Rights: 4,114,871,233.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the commencement of the buyback programme on February 24, 2025, GSK has purchased an aggregate of 31,296,922 ordinary shares. The April 22 transaction represents the latest execution under this programme. The total number of voting rights remains consistent with the number of shares in issue, as treasury shares do not carry voting rights.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These factors are referenced as being described in the Risk Factors section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F. No specific new guidance or management commentary regarding future financial performance is provided in this document.
Investor Verification Checklist
- Verify the total cumulative buyback volume since February 24, 2025 (31,296,922 shares).
- Confirm the current number of shares in issue (4,114,871,233) for disclosure threshold calculations under FCA rules.
- Review the GSK 2024 Annual Report on Form 20-F for detailed risk factors referenced in the cautionary statement.
- Monitor subsequent filings for updates on the remaining capacity or duration of the existing buyback programme.